Topics:
Genitourinary Cancers • Medical Oncology • Renal Cell Carcinoma • NCI-CCC Tumor Board Question • UCSF • NCI-CCC GU Tumor Board Question
In a patient with metastatic clear cell RCC who achieved a prolonged PR with first line nivolumab/ipilimumab, discontinued due to IRAEs, would you consider a TKI/checkpoint inhibitor combination regimen?
In this case, nivo/ipi discontinued for immune-related arthralgias requiring steroids and an anti-TNFa agent, now off all immunosuppression.
Answer from: Medical Oncologist at Academic Institution
The question of the utility of IO after IO in mRCC is an important one that has not yet been adequately studied. As of now, I believe single agent VEGF TKI is standard of care in this setting (or perhaps lenvatinib/everolimus). There are some retrospective data about Ipi/nivo after prior IO with som...
Sign in or Register to read more